Acutaas Chemicals (ACUTAAS) Q1 24/25 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 24/25 earnings summary
10 Feb, 2026Executive summary
Q1 FY25 revenue grew 16.6% year-over-year, primarily driven by advanced pharmaceutical intermediates and robust CDMO activity, with specialty chemicals growing 10% but Baba Fine Chemicals underperforming due to integration and demand issues.
Unaudited standalone and consolidated financial results for Q1 ended June 30, 2024, were approved by the Board and reviewed by statutory auditors with no modifications.
Q1 is historically the lowest revenue quarter, with sequential growth expected through the year and management reaffirming 25% annual growth guidance.
The company successfully completed PMDA (Japan) and USFDA inspections, enhancing regulatory credentials and opening new market opportunities.
Financial highlights
Q1 FY25 consolidated revenue: INR 176.7 crore (Rs. 1,767 mn), up 16.6% year-over-year; standalone revenue: ₹17,113.70 lakhs, up from ₹14,235.08 lakhs in Q1 FY24.
Gross profit: INR 74.3 crore, up 1% year-over-year; gross margin at 42.1%, down from 47.9% in Q1 FY24 but up from 40% in Q4 FY24.
EBITDA: INR 29.5 crore, down 13.2% year-over-year; EBITDA margin at 16.7%, down from 22.1% last year.
PAT for Q1 FY25 was INR 14.7 crore, with a PAT margin of 8.3%, impacted by increased finance and depreciation costs.
Net cash on hand as of June: INR 385 crore; net debt zero status achieved after raising Rs. 500 crore and repaying Rs. 253 crore debt.
Outlook and guidance
Management reaffirms 25% revenue growth guidance for FY 2025, with sequential improvement expected in coming quarters based on the current order book.
EBITDA margin expected to improve by 200 basis points in subsequent quarters due to operational leverage and margin normalization.
Full ramp-up of new CDMO contracts and Ankleshwar blocks expected by FY 2026.
Tax rate for FY 2025 expected to be slightly above 25%.
Proceeds from recent equity issues are earmarked for growth and operational objectives, with significant unutilized funds in fixed deposits.
Latest events from Acutaas Chemicals
- Q1 FY26 revenue up 17.3% YoY, profit surged, and new South Korea JV supports 25% growth outlook.ACUTAAS
Q1 25/263 Feb 2026 - Record Q3 FY26 revenue, margins, and PAT; FY26 guidance raised on multi-segment growth.ACUTAAS
Q3 25/263 Feb 2026 - Q3 FY25 revenue up 65.2% YoY, PAT more than doubled, and FY25 growth guidance raised to 35%.ACUTAAS
Q3 24/2520 Dec 2025 - Q2 FY 2025 revenue up 43.2% YoY, PAT up 155%, and FY 2025 growth guidance raised to 30%.ACUTAAS
Q2 24/2519 Dec 2025 - FY25 revenue surpassed ₹10,000 million, with strong profit growth and 25% growth targeted for FY26.ACUTAAS
Q4 24/2519 Dec 2025 - Q2 FY26 saw strong revenue and profit growth, major investments, and a share split.ACUTAAS
Q2 25/2618 Dec 2025